BGJ398 (infigratinib)
CBGJ398X2204
Phase 2 small_molecule terminated
Quick answer
BGJ398 (infigratinib) for Advanced Cholangiocarcinoma is a Phase 2 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Advanced Cholangiocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated